Palo Santo

Palo Santo is a U.S.-based venture capital firm focused on increasing the supply of clinically effective and accessible mental health and addiction treatment solutions. The firm targets a diverse range of companies offering innovative solutions across biopharma, drug development, digital therapeutics, healthcare services, and tech-enabled solutions to address the growing global mental health crisis. From cutting-edge science to commercial application, Palo Santo's portfolio includes more than 20 companies focused on advancing the field of psychedelic medicines and expanding patient access and affordability.

The firm has made significant investments in companies such as atai Life Sciences, Reset Pharma, Field Trip Health, Tactogen, Eleusis, Bexson Biomedical, Ksana Health, neuroCare, Bright Minds, Diamond Therapeutics, and Gilgamesh, among others. Palo Santo's team brings decades of experience in investing and portfolio building in private equity and venture capital, along with expertise in life sciences and healthcare services. Additionally, the firm is supported by leading academics and advisors in psychedelic science.

Palo Santo's mission is to drive clinical development and FDA approval of psychedelic therapies that are poised to become the future standard of care. The firm actively works to support and synergize its portfolio by connecting founders, advisors, and key opinion leaders with a collaborative ethos in mind. By investing in early-stage, high-growth opportunities, Palo Santo aims to have a profound impact on treating a wide range of conditions such as depression, PTSD, anxiety, OCD, addiction, chronic or neuropathic pain, neurodegenerative diseases, and a range of inflammatory-related illnesses.